REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors
From MaRDI portal
Cites work
- A Bayesian phase I/II trial design for immunotherapy
- A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
- An information theoretic phase I--II design for molecularly targeted agents that does not require an assumption of monotonicity
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
- Bayesian optimal interval designs for phase I clinical trials
- Change-point joint model for identification of plateau of activity in early phase trials
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Design and Analysis of Phase I Clinical Trials
- Determining the Effective Sample Size of a Parametric Prior
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Group up-and-down designs for dose-finding
- scientific article; zbMATH DE number 2242805 (Why is no real title available?)
- Phase I--II trial design for biologic agents using conditional auto-regressive models for toxicity and efficacy
- Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors
This page was built for publication: REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6618357)
